Edesa Biotech, Inc.
- Open
- 7.99
- Day high
- 7.99
- Day low
- 7.65
- Prev close
- 8.13
- Volume
- 20K
- Mkt cap
- $70M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.8
- P/S
- —
- Yield
- —
- Per share
- —
Edesa Biotech, Inc. (EDSA) is a Healthcare company listed on NASDAQ. The stock is up 300% over the past year.
Edesa Biotech, Inc. (EDSA) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
EDSA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 14, 2026 | $-0.24 | $-0.49 | -104.2% | — | — |
| Feb 13, 2026 | $-0.28 | $-0.28 | +0.0% | — | — |
| Dec 12, 2025 | $-0.27 | $-0.32 | -18.5% | — | — |
| Aug 8, 2025 | $-0.26 | $-0.25 | +3.8% | — | — |
| May 14, 2025 | $-0.30 | $-0.30 | +0.0% | — | — |
| Feb 14, 2025 | $-0.31 | $-0.48 | -54.8% | — | — |
| Dec 13, 2024 | $-0.54 | $-0.29 | +46.3% | — | — |
| Aug 9, 2024 | $-0.58 | $-0.52 | +10.3% | — | — |
| May 10, 2024 | $-0.69 | $-0.58 | +15.9% | — | — |
| Feb 9, 2024 | $-1.21 | $-0.54 | +55.4% | — | — |
| Dec 15, 2023 | $-0.71 | $-0.60 | +15.5% | $-1M | — |
| May 11, 2023 | $-1.19 | $-0.84 | +29.4% | — | — |
EDSA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 16, 2026 | Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer | Grant | 153,550 | — |
| Jun 1, 2026 | Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer | Grant | 1,671 | — |
| May 29, 2026 | MacDonald Sean Arthurdirector | Grant | 19,000 | — |
| May 29, 2026 | Chypyha Joandirector | Grant | 19,000 | — |
| May 29, 2026 | Weiler Peter J.officer: Chief Financial Officer | Grant | 64,609 | — |
| May 29, 2026 | Brooks Michael Jofficer: President | Grant | 64,609 | — |
| May 29, 2026 | Sistilli Carlodirector | Grant | 19,000 | — |
| May 29, 2026 | Olson Charles Vdirector | Grant | 19,000 | — |
| May 29, 2026 | Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer | Grant | 96,913 | — |
| May 29, 2026 | Liu Da Daviddirector | Grant | 19,000 | — |
| May 29, 2026 | Marshall Patrickdirector | Grant | 19,000 | — |
| May 1, 2026 | Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer | Grant | 1,159 | — |
| Apr 10, 2026 | Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer | Grant | 2,578 | — |
| Mar 11, 2026 | Brooks Michael Jofficer: President | Buy | 2,000 | $1.57 |
| Mar 6, 2026 | Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer | Buy | 10,000 | $3.90 |
Source: EDSA SEC Form 4 filings, latest Jun 16, 2026. For informational purposes only — not investment advice.
See the full EDSA insider & 13F page →Edesa Biotech, Inc. company profile
Overview
Edesa Biotech, Inc. (NASDAQ:EDSA) is a Canadian biopharmaceutical company founded in 2015 and headquartered in Markham, Ontario. The company went public in 2010 and focuses on acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases. As a clinical-stage biotechnology firm, Edesa operates without generating revenue from product sales, instead relying on funding to advance its drug candidates through various phases of clinical trials toward potential regulatory approval and commercialization.
Business
Edesa Biotech operates in the biotechnology sector, specifically focusing on developing treatments for inflammatory and immune-related diseases that have significant unmet medical needs. The company's business model centers on in-licensing promising drug candidates from other organizations and then advancing them through clinical development. The company's lead product candidate is EB05, a monoclonal antibody currently in Phase 3 clinical trials for treating acute respiratory distress syndrome (ARDS) in COVID-19 patients. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens. ARDS is a severe lung condition that causes fluid to leak into the lungs, making breathing difficult and potentially fatal. This condition became particularly relevant during the COVID-19 pandemic as a major cause of death among severely ill patients. The company's second key asset is EB01, a topical treatment currently in Phase 2B clinical trials for chronic allergic contact dermatitis. This condition occurs when the skin has an allergic reaction to substances it comes into contact with, causing persistent inflammation, redness, and discomfort. Current treatment options are limited, creating an opportunity for new therapeutic approaches. Edesa has established a licensing agreement with NovImmune SA, a Swiss biotechnology company, to develop monoclonal antibodies that target specific immune system pathways (TLR4 and CXCL10). These targets are involved in inflammatory responses and represent potential therapeutic opportunities for various immune-related conditions.
Revenue model
As a clinical-stage biopharmaceutical company, Edesa currently generates no revenue from product sales, as evidenced by zero revenue reported across all recent financial periods. The company's business model is built around advancing drug candidates through clinical trials with the ultimate goal of achieving regulatory approval and either commercializing the products directly or licensing them to larger pharmaceutical companies. The company's funding comes primarily from equity financing, as indicated by its substantial cash positions in recent quarters and lack of significant debt. Biotech companies like Edesa typically raise capital through public offerings, private placements, or strategic partnerships to fund their research and development activities. Several factors could significantly impact Edesa's future profitability and margins. Success in clinical trials, particularly the Phase 3 trial for EB05, could dramatically increase the company's valuation and attract partnership opportunities with major pharmaceutical companies. Regulatory approval from agencies like the FDA would enable product commercialization and revenue generation. Conversely, clinical trial failures, regulatory setbacks, or competitive developments could severely impact the company's prospects. The COVID-19 context for EB05 presents both opportunity and risk - while the pandemic highlighted the need for ARDS treatments, the evolving nature of the pandemic and potential changes in treatment protocols could affect market demand. For EB01, the chronic nature of allergic contact dermatitis represents a more stable market opportunity, though competition from established dermatology treatments remains a consideration. The company's cash burn rate, currently running at approximately $1.5-2.4 million per quarter based on recent operating cash flows, determines how long the company can continue operations without additional funding. This creates ongoing pressure to achieve clinical milestones that can attract additional investment or partnership opportunities.
Competitive moat
Edesa Biotech operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages or moats. The company's primary assets are its licensed drug candidates and clinical trial data, but these represent relatively weak moats compared to established pharmaceutical companies. The company's main competitive position stems from its licensing agreement with NovImmune SA for specific monoclonal antibody targets (TLR4 and CXCL10), which provides some exclusivity in developing treatments targeting these pathways. However, this advantage is limited by the scope of the licensing agreement and the potential for competitors to develop alternative approaches targeting the same diseases. The clinical trial progress, particularly the Phase 3 status of EB05 for ARDS treatment, represents a temporary competitive advantage through timing - being among the first to market with an effective ARDS treatment could provide significant first-mover benefits. However, this advantage is fragile and depends entirely on successful trial outcomes and regulatory approval. The company faces substantial competitive threats from larger pharmaceutical companies with greater resources, more diversified pipelines, and established commercial capabilities. Major pharmaceutical companies could develop competing treatments, acquire competitors with similar or superior assets, or simply outspend smaller biotechs in clinical development. The biotechnology sector's inherent risks - including clinical trial failures, regulatory rejections, and the high cost of drug development - mean that even promising early-stage results may not translate into commercial success. Edesa's small size and limited financial resources make it particularly vulnerable to setbacks that larger, more diversified companies could better absorb. Overall, Edesa's competitive position is weak, relying primarily on execution risk and timing rather than sustainable competitive advantages. The company's success depends heavily on clinical trial outcomes and the ability to secure partnerships or funding to advance its programs.
Risks & safety
Edesa Biotech presents a mixed margin of safety profile typical of early-stage biotechnology companies, with strong liquidity but high execution risk. • Cash and Liquidity Position: The company significantly improved its cash position in Q2 2025, reporting $13.9 million in cash and short-term investments compared to $1.6 million in Q1 2025, indicating a successful capital raise. Current ratio of 15.7x provides excellent short-term liquidity coverage. • Debt and Solvency: Minimal debt burden with debt-to-equity ratio near zero across all periods. No significant solvency risk from debt obligations. • Cash Burn Analysis: Quarterly operating cash flow burn of approximately $1.5-2.4 million suggests the current cash position provides roughly 6-9 quarters of runway at current spending levels, though this could accelerate with Phase 3 trial costs. • Valuation Metrics: Trading at 0.83x price-to-book ratio as of Q2 2025, suggesting the stock trades below book value. However, traditional valuation metrics are less meaningful for pre-revenue biotechs. • Financial Stability Concerns: Zero revenue generation and consistent losses ($6.2 million net loss in FY 2024) create ongoing funding dependency. The company's survival depends entirely on successful clinical outcomes or continued access to capital markets. • Asset Quality: Most assets are cash-based rather than productive assets, with limited tangible book value beyond clinical trial investments and intellectual property rights.
Recent development
Based on the available financial data, Edesa Biotech has been primarily focused on advancing its two key clinical programs while managing its capital structure. The most significant recent development appears to be a substantial capital raise that occurred between Q1 and Q2 2025, increasing the company's cash position from $1.6 million to $13.9 million. This financing provides crucial runway for continuing clinical operations. The company has maintained its focus on advancing EB05 through Phase 3 clinical trials for ARDS treatment in COVID-19 patients, representing its most advanced and potentially valuable asset. Simultaneously, the company continues developing EB01 for chronic allergic contact dermatitis through Phase 2B trials. Financial management has been a key focus, with the company carefully managing its cash burn rate while maintaining minimal debt obligations. The quarterly operating losses have remained relatively stable, ranging from approximately $1.0 million to $2.4 million per quarter, suggesting disciplined spending on clinical activities. The company's strategic approach appears centered on advancing its clinical programs to key inflection points where they could attract partnership interest from larger pharmaceutical companies or achieve regulatory milestones that would significantly enhance valuation. The licensing relationship with NovImmune SA continues to provide the foundation for the company's monoclonal antibody development programs. Without access to detailed earnings call transcripts, the specific strategic decisions and management commentary on future directions are not available, but the financial trajectory suggests a company focused on clinical execution while maintaining financial flexibility through periodic capital raises.
EDSA company profile · for informational purposes only — not investment advice.
Track EDSA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free